Resources
What the literature actually examines.
36 articles on the compounds in this catalog — what each molecule is, what has been investigated, how far the evidence went, and what a regulator has said about it. Written for someone deciding what to order, with the papers cited so you can read them yourself.
These summaries describe published research. They are not instructions for use, contain no amounts or schedules, and make no claim about what any compound does in a person. Every product on this site is supplied for laboratory research use only.
Testing and handling · 5
- 7 min
HPLC and LC-MS in peptide testing: what each method can actually see
HPLC answers how much. Mass spectrometry answers what. Neither answers the other, and a report with only one of them has a blind spot you can name.
- 7 min
Lyophilised peptides: what the cake is, and what degrades it
Freeze-drying buys stability by removing water. What the dried cake is, the chemistry still proceeding inside it, and why no expiry is published.
- 7 min
What a peptide certificate of analysis establishes, and what no certificate can
A certificate reports on one batch, on one day, from a laboratory the seller chose and paid. What each test measures, and the gaps none of them cover.
- 8 min
How to read a peptide study: design, controls and the limits of a result
The evidence hierarchy, the controls that make a result mean something, why small studies mislead, and how often animal findings fail to carry over.
- 7 min
Handling research peptides in the laboratory: from receipt to aliquot
What happens to a peptide after the certificate was written is your record, not the supplier's. Receipt, dissolution, aliquoting, documentation.
Foundations · 4
- 8 min
How peptide receptor signalling is studied: binding, activation and what an assay result means
Affinity, potency and efficacy are three different things. What radioligand binding, cAMP and arrestin assays measure, and where each one stops.
- 8 min
A working glossary of peptide research terms
Thirty-two terms you meet reading peptide literature, certificates of analysis and regulatory pages, each defined in a sentence or two.
- 7 min
Peptides and Canadian law: how Health Canada regulates drugs, and where research-use material sits
What market authorisation means, why a research chemical is not a medicine, and which questions only a lawyer or the regulator can answer.
- 7 min
Peptides explained: what they are, how they are made, and what their literature can establish
What a peptide is chemically, where these sequences come from, how they are made, and why nearly all of their literature is preclinical.
5-Amino-1MQ · 2
- 6 min
5-Amino-1MQ is not a peptide: what NNMT inhibition is, and how far the work goes
5-Amino-1MQ is a small molecule filed in peptide catalogues. What NNMT does, what three papers reported, and where the evidence stops.
- 7 min
5-Amino-1MQ and aged muscle stem cells: one paper, and what it reported
The muscle thread for 5-Amino-1MQ rests on a single 2019 paper in aged mice. What it examined, the mechanism it proposed, and what is missing.
Blends · 2
- 8 min
Inside the KLOW blend: the four components, and how far the literature on each one goes
KLOW is 80 mg in one vial: BPC-157, GHK-Cu, TB-500 and KPV. What each component's literature examined, and why four compounds means four sets of unknowns.
- 8 min
Wolverine Stack and the GLOW blend: what the third component changes
Both formulations are BPC-157 and TB-500; GLOW adds GHK-Cu. What each component's literature examined, why total milligrams mislead, and where the evidence stops.
GHK-Cu · 2
- 7 min
GHK-Cu and photoageing: what the UV-damage literature actually examines
The GHK-Cu photoageing literature is cell-culture and cosmetic-formulation work, much of it reviewed by the people who identified the peptide.
- 7 min
GHK-Cu and wound repair: the literature the copper-peptide field was built on
The founding GHK-Cu result is collagen synthesis in fibroblast culture. Here is what the repair literature examined, and what it never established.
GLP-1 and metabolic · 2
- 7 min
Retatrutide and the triple agonist idea: what the trials examined and what is still unknown
Retatrutide is investigational and approved by no regulator anywhere. Here is what its published trials examined and what they reported.
- 7 min
Tirzepatide and retatrutide: two receptor counts, two completely different regulatory positions
Tirzepatide is an approved medicine; retatrutide is approved nowhere. What each trial programme examined, and why no head-to-head exists.
Growth hormone peptides · 2
- 8 min
CJC-1295 and ipamorelin: three molecules, two names, and which papers describe what
Most of the CJC-1295 trial literature concerns the DAC version, which is not what is sold as CJC-1295. Ipamorelin acts on a different receptor entirely.
- 7 min
Ipamorelin and somatopause: a research hypothesis, not an established condition
Somatopause is a descriptive term for age-related GH decline, and whether it is pathology or adaptation is unsettled. Ipamorelin is approved nowhere.
KPV · 2
- 7 min
KPV and airway inflammation: how far the α-MSH evidence actually reaches
The airway literature here is α-MSH work, not KPV work. This sets out the chain of inference, where it breaks, and why no asthma trial exists.
- 7 min
KPV and the colitis literature: what the PepT1 papers actually examined
The KPV gut literature rests on two 2008 papers in mice and one transporter mechanism. Here is what they examined and where the evidence stops.
Selank · 2
- 6 min
Selank and learning: reading the avoidance-reflex and BDNF papers closely
The Selank cognition literature is a handful of papers, mostly Russian. What they measured, what they never looked at, and why the difference matters.
- 7 min
Selank and the stress axis: a well-described system and a thin literature
The HPA axis is well understood. Selank's place in it is not: no published work cited here measured cortisol. What the papers examined instead.
Semax · 2
- 6 min
N-Acetyl Semax Amidate and Semax: what the two extra caps change
Semax is already a modified peptide. The acetylated, amidated version is modified twice more — at the ends only. What that does, and what it does not.
- 7 min
Semax and cerebral ischaemia: what the ACTH(4-10) literature examined
Semax is a registered medicine in Russia and approved nowhere else. Here is what the published ischaemia work measured, and what it does not establish.